YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Ironwood Pharmaceuticals' IRWD sole marketed product, Linzess (linaclotide), is witnessing strong prescription demand and uptake in recent times. The company has a partnership with drug giant AbbVie ABBV to jointly develop and commercializ…
[mrna Cancer Vaccine] wildpixel/iStock via Getty Images INVESTORS SHOULD KNOW: Personalized mRNA cancer vaccines are moving beyond their first major clinical success in melanoma into a broader test across harder-to-treat solid tumors. The…
[Ozempic Insulin injection pen] CR/iStock via Getty Images INVESTORS SHOULD KNOW: The obesity drug market is undergoing a structural shift, moving beyond the initial injectable GLP-1 franchise. Now, the industry is moving toward a broader…
Ironwood Pharmaceuticals IRWD reported adjusted earnings of 31 cents per share for the second quarter of 2026, surpassing the Zacks Consensus Estimate of 26 cents. The company had reported adjusted earnings of 14 cents per share in the yea…
[Stock market activity shows price changes and trading movements in real time] FabrikaCr As the market moves through second-quarter earnings season, investors are paying close attention to small-cap stocks that combine solid profitability…
Community Health Systems, Inc. CYH reported a second-quarter 2026 net loss of 19 cents per share, missing the Zacks Consensus Estimate of a loss of 18 cents. The bottom line deteriorated significantly from a loss of 5 cents per share in th…
UnitedHealth Group Incorporated UNH reported second-quarter 2026 adjusted earnings per share (EPS) of $6.38, which beat the Zacks Consensus Estimate of $4.94. The bottom line rose 56.4% year over year. Revenues rose 0.4% year over year to…
(RTTNews) - Ironwood Pharmaceuticals Inc. (IRWD) has named Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development, following the retirement of Dr. Michael Shetzline after a distinguished 30-year career in gas…
BioCryst Pharmaceuticals (BCRX) shares ended the last trading session 8.1% higher at $10.99. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 20.6…
Tech stocks have been suffering over the past few weeks, as investors continue to rotate out of the artificial intelligence (AI)-focused tech and semiconductor stocks due to growing concerns over their sustainability. Despite a solid first…
Thursday, July 2, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Applied Materials, Inc. (AMAT), Mastercard Inc. (MA)…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images Healthcare stocks have remained in focus as investors look for companies that can deliver strong operational growth w…
Ironwood Pharmaceuticals’ IRWD sole marketed product, Linzess (linaclotide), has witnessed a strong uptake in recent times. The company has a partnership with AbbVie ABBV to jointly develop and commercialize Linzess in the United States. L…
The targeted oncology sector is shifting after GSK (GSK [https://seekingalpha.com/symbol/GSK]) decided to buy [https://seekingalpha.com/news/4601644-gsk-to-buy-nuvalent-for-106b] Nuvalent (NUVL [https://seekingalpha.com/symbol/NUVL]) for $…
We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is one of the most undervalued stocks to invest in. TheFly reported on May 27 that IRWD reported that the U.S.…
Image source: The Motley Fool. Date Thursday, May 7, 2026 at 8:30 a.m. ET Call participants Chief Executive Officer — Thomas McCourt Chief Commercial Officer — Tammi Gaskins Chief Medical Officer — Michael Shetzline Chief Financial Officer…
Ironwood Pharmaceuticals IRWD announced that the FDA has approved the expanded use of its sole marketed drug, Linzess (linaclotide), for the treatment of functional constipation (FC) in pediatric patients aged two years and older. The ther…
(RTTNews) - Ironwood Pharmaceuticals Inc. (IRWD), a biotechnology company, on Wednesday announced approval from the U.S Food and Drug Administration (FDA) for the use of LINZESS in patients aged 2 years and older in treating functional con…
We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is among the best small cap pharma stocks. TheFly reported on May 7 that IRWD reported its first-quarter 2026…
Ironwood Pharmaceuticals IRWD reported adjusted earnings of 24 cents per share for the first quarter of 2026, surpassing the Zacks Consensus Estimate of 7 cents. The company had reported an adjusted loss of 14 cents per share in the year-a…
Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) is one of the 7 best small-cap drug manufacturing stocks to buy according to hedge funds. On February 26, Citizens analyst Jason Butler maintained an Outperform rating on Ironwood Pharmaceuticals…
Shares of Ironwood Pharmaceuticals IRWD have witnessed a sharp decline over the past month, primarily due to softer sales of its sole marketed product, Linzess (linaclotide), during the fourth quarter of 2025. The stock has plunged 14.2% o…
It has been about a month since the last earnings report for Ironwood Pharmaceuticals (IRWD). Shares have lost about 13.9% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend…
Sarissa Capital Management established a new position in Biohaven Ltd.(NYSE:BHVN) during the fourth quarter, acquiring 513,184 shares worth $5.79 million at quarter’s end, according to a February 17, 2026, SEC filing. What happened Accordi…
[Black Bull and Bear] peterschreiber.media/iStock via Getty Images Small-cap outperformance has narrowed over the last couple of weeks as investor caution increased, with volatility and geopolitical risk weighing on risk appetite and narro…
Ironwood Pharmaceuticals IRWD and Puma Biotechnology PBYI are small-cap biotech firms that depend largely on the successful commercialization of a single key drug while trying to broaden their relatively limited pipelines. Each company con…
Ironwood Pharmaceuticals’ IRWD sole marketed product, Linzess (linaclotide), is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients aged seven years and above. The drug is also…
Ironwood Pharmaceuticals IRWD reported an adjusted loss of 1 cent per share for the fourth quarter of 2025, against the Zacks Consensus Estimate of earnings of 2 cents. The company had reported adjusted earnings of 1 cent per share in the…
Ironwood Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Execution and Performance Drivers Delivered 11% LINZESS prescription demand growth in 2025, maintaining a 45% market share despite net price erosion from Medicar…
Image source: The Motley Fool. DATE Wednesday, Feb. 25, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Tom McCourtChief Medical Officer — Michael ShetzlineChief Financial Officer — Greg MartiniChief Commercial Officer — T…
Image source: The Motley Fool. DATE Wednesday, Feb. 25, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Tom McCourt Chief Medical Officer — Michael Shetzline Chief Financial Officer — Greg Martini Chief Commercial Officer…
The fourth-quarter 2025 earnings season for the Medical sector is nearing its close, with just a few pharma and biotech companies left to report. Overall, the sector has delivered a fairly solid performance so far. Per the Earnings Trends…
Ironwood Pharmaceuticals IRWD and Bausch Health BHC operate in the branded gastrointestinal (GI) drug market, with a focus on treatments for irritable bowel syndrome (IBS) and other therapeutic areas. While Ironwood is a smaller, more focu…
Waters Corporation WAT reported fourth-quarter 2025 non-GAAP earnings of $4.53 per share, which beat the Zacks Consensus Estimate by 0.67% and increased 10.5% year over year. Net sales of $932.4 million topped the Zacks Consensus Estimate…
Shares of Ironwood Pharmaceuticals IRWD have risen sharply over the past six months, primarily driven by the improving demand for its sole marketed product, Linzess (linaclotide) and the company’s upbeat 2026 revenue guidance. The stock ha…
Coins on a table beside a phone showing a rising green stock chart. Key Points Analysts expect these three stocks trading near $5 to deliver earnings growth of 74% to 150%. Each company has a near-term catalyst, including upcoming earnings…